Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study

Laurent, Christian, Diakhaté, Ndella, Fatou Ngom Gueye, Ndeye, Awa Touré, Mame, Salif Sow, Papa, Awa Faye, Mame, Gueye, Mandoumbé, Lanièce, Isabelle, Touré Kane, Coumba, Liégeois, Florian, Vergne, Laurence, Mboup, Souleymane, Badiane, Salif, Ndoye, Ibrahima, Delaporte, Eric·2002·AIDS

Abstract

OBJECTIVE: To study the feasibility, effectiveness, adherence, toxicity and viral resistance in an African government HAART initiative. METHODS: A prospective observational cohort study started in Dakar in August 1998. Initial treatment consisted of two nucleoside reverse transcriptase inhibitors and one protease inhibitor. The patients attended monthly medical examinations. Plasma HIV-1 RNA and CD4 cell counts were determined at baseline and every 6 months. Intention-to-treat analyses were performed. RESULTS: Fifty-eight treatment-naive patients, mostly infected by HIV-1 strain CRF02-AG, were enrolled. Most were at an advanced stage of HIV disease (86.2% had AIDS). Adherence was good in 87.9% of patients and treatment was effective in most of them. Thus, HIV-1 RNA was undetectable in 79.6, 71.2, 51.4 and 59.3% of patients at months 1, 6, 12 and 18, respectively and the median viral load reduction was approximately 2.5 log10 copies/ml. The CD4 cell count rose by a median of 82, 147 and 180 x 106 cells/l at months 6, 12 and 18, respectively. At the same time points, the cumulative probability of remaining alive or free of new AIDS-defining events was 94.8, 85.0 and 82.3%. Most adverse effects (80.8%) were mild or moderate and only two cases of drug resistance occurred. CONCLUSION: This study shows that HAART is feasible and well tolerated in African patients. Clinical and biological results were comparable to those seen in western cohorts, despite differences in the HIV-1 subtype distribution and an advanced disease stage when the treatment was initiated. Contrary to other recent studies in Africa, viral resistance rarely emerged.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00002030-200207050-00008

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 272

Metadata

Authors
Laurent, C., Diakhaté, N., Fatou Ngom Gueye, N., Awa Touré, M., Salif Sow, P., Awa Faye, M., Gueye, M., Lanièce, I., Touré Kane, C., Liégeois, F., Vergne, L., Mboup, S., Badiane, S., Ndoye, I., & Delaporte, E.
Venue
AIDS
Published
2002-07
Volume
16
Issue
10
Pages
1363-1370
ISSN
0269-9370 (ISSN-L)
OpenAlex
W2094514022
Cited by
272
References
17
FWCI
17.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. https://app.cochat.ai/papers/10.1097/00002030-200207050-00008
The paper
Laurent, C., Diakhaté, N., Fatou Ngom Gueye, N., Awa Touré, M., Salif Sow, P., Awa Faye, M., Gueye, M., Lanièce, I., Touré Kane, C., Liégeois, F., Vergne, L., Mboup, S., Badiane, S., Ndoye, I., & Delaporte, E. (2002). The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. https://doi.org/10.1097/00002030-200207050-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.